Advertisement

Search Results

Advertisement



Your search for all items matches 34052 pages

Showing 101 - 150


lung cancer

TROPION-Lung01 Update: Dato-DXd Shows Activity in Previously Treated Advanced Nonsquamous NSCLC

The novel trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) vs docetaxel conferred a numerical improvement in overall survival in previously treated patients with advanced non–small cell lung cancer (NSCLC), according to the phase III,...

lung cancer

CARMEN-LC03: Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC

The multicenter phase III CARMEN-LC03 trial did not meet its dual primary endpoints of progression-free and overall survival with the CEACAM5-directed antibody-drug conjugate tusamitamab ravtansine vs standard chemotherapy with docetaxel in previously treated patients with advanced nonsquamous...

lung cancer

New Hope for Patients With HER2-Mutant NSCLC: Durable Responses to Two Novel Targeted Therapies

Two novel oral HER2 tyrosine kinase inhibitors have demonstrated promising efficacy in patients with HER2-mutant non–small cell lung cancer (NSCLC), potentially transforming the treatment landscape for this challenging subset of lung cancer cases. According to data presented at the International...

lung cancer

Novel EGFR Inhibitor Firmonertinib Shows Activity in Rare Subtype of NSCLC

Firmonertinib (AST2818; formerly furmonertinib), a novel EGFR inhibitor, has shown activity and tolerability in patients with advanced non–small cell lung cancer (NSCLC) harboring EGFR P loop and aC-helix compressing (PACC) mutations, according to data presented at the International Association for ...

Osimertinib Plus Savolitinib: Responses Reported in First-Line Treatment of MET-Aberrant, EGFR-Mutant NSCLC

The combination of the EGFR tyrosine kinase inhibitor osimertinib and the MET inhibitor savolitinib has demonstrated clinically meaningful improvements compared with osimertinib alone as a first-line treatment of patients with de novo MET-aberrant, EGFR-mutant advanced non–small cell lung cancer...

lung cancer

Amivantamab-vmjw Plus Lazertinib Improves Long-Term Outcomes in First-Line Setting of EGFR-Mutant Advanced NSCLC

The combination of the EGFR-MET bispecific antibody amivantamab-vmjw and the EGFR tyrosine kinase inhibitor lazertinib continues to demonstrate superior efficacy compared with the kinase inhibitor osimertinib alone in the first-line treatment of EGFR-mutant advanced non–small cell lung cancer...

lung cancer

HARMONi-2: Ivonescimab Outperforms Pembrolizumab as First-Line Treatment in NSCLC

In a phase III study conducted in China, the bispecific antibody (targeting both PD-1 and the vascular endothelial growth factor [VEGF]) ivonescimab was compared with the PD-1 inhibitor pembrolizumab as first-line treatment of PD-L1–positive advanced non–small cell lung cancer (NSCLC). Ivonescimab ...

lung cancer

‘Encouraging’ Pathologic Responses Achieved With Novel Combination Regimen in Early-Stage NSCLC

In the multiarm phase II NeoCOAST-2 trial, neoadjuvant treatment with datopotamab deruxtecan (Dato-DXd) plus the monoclonal antibody durvalumab and single-agent platinum chemotherapy led to promising rates of pathologic complete and major pathologic responses in patients with early-stage non–small...

lung cancer

Patient-Level Data Support Perioperative Use of Nivolumab in Resectable NSCLC

An examination of patient-level data from the phase III CheckMate 816 and CheckMate 77T trials supports the perioperative use of the PD-1 inhibitor nivolumab plus chemotherapy, as compared with the neoadjuvant use of nivolumab plus chemotherapy without adjuvant therapy, in resectable non–small...

prostate cancer
survivorship

Study Finds Long-Term Risks Associated With Prostate Cancer Treatment

A large cohort study investigated the long-term treatment-related adverse effects and complications from prostate cancer treatment compared with an untreated control group. The investigators found that treatment was associated with higher rates of 10 potential complications in the 12 years after...

lung cancer

Highlights From the 2024 World Conference on Lung Cancer

At the 2024 World Conference on Lung Cancer (WCLC), more than 7,000 clinicians and scientists gathered in San Diego in celebration of the 50th anniversary of the International Association for the Study of Lung Cancer (IASLC). In this supplement to The ASCO Post, we review impactful abstracts from...

thyroid cancer

Nivolumab Plus Ipilimumab in Aggressive Thyroid Carcinoma

In a single-institution phase II study reported in JAMA Oncology, Sehgal et al found evidence of activity of nivolumab plus ipilimumab in patients with aggressive thyroid carcinoma. Study Details In the trial, 49 evaluable patients enrolled at Dana-Farber Cancer Institute between October 2017 and...

integrative oncology
symptom management

Participation in Virtual Prehabilitation and Outcomes Following Thoracic Cancer Surgery

Guest Editor’s Note: Oncology guidelines recommend prehabilitation exercises to minimize postoperative complications. However, the COVID-19 pandemic imposed severe restrictions on patient access to in-person exercise programs offered by hospitals and clinics. In this article, Dr. Krupali Desai...

breast cancer

Trastuzumab Duocarmazine in Previously Treated HER2-Positive Metastatic Breast Cancer

In the phase III TULIP trial reported in the Journal of Clinical Oncology, Turner et al found that the third-generation HER2-targeted antibody-drug conjugate trastuzumab duocarmazine (T-Duo) improved progression-free survival vs physician's choice (PC) of treatment in patients with previously...

solid tumors
issues in oncology
genomics/genetics

NCCN Guidelines Have Expanded to Meet Growing Understanding of Hereditary Risk

The National Comprehensive Cancer Network (NCCN) introduced expanded NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) to account for the advanced understanding of hereditary cancer risk in breast, ovarian, pancreatic, and prostate cancers. The new guidelines followed the recent...

skin cancer
issues in oncology

Tanning Bed Access, Usage May Be Driving Higher Rates of Melanoma in New England

Investigators have uncovered a potential link between the availability and use of tanning beds and the rising rates of melanoma in New England, according to a recent study published by Wei et al in the Journal of Investigative Dermatology. The findings may provide critical insights to inform public ...

solid tumors
cardio-oncology
covid-19

Study Explores Underpinnings of Immunotherapy-Releated Myocarditis in Patients With Cancer

Researchers may have uncovered the immune basis for the development of myocarditis in patients with cancer receiving immune checkpoint inhibitors, according to a recent study published by Blum et al in Nature. The findings revealed changes in specific types of immune and stromal cells in the heart...

lung cancer
issues in oncology

Detecting Evidence of Lung Cancer in Exhaled Breath

Researchers may have developed ultrasensitive, nanoscale sensors that distinguished a key change in the chemistry of the breath of patients with lung cancer, according to a recent study published by Cheng et al in ACS Sensors. Background Individuals breathe out many gases, such as water vapor and...

lung cancer

SITC: Study Finds IO102-IO103 Vaccine Plus Pembrolizumab Active in Patients With Non–Small Cell Lung Cancer

A phase II study by Riess et al investigating the IO102-IO103 vaccine plus pembrolizumab as first-line treatment in patients with non–small cell lung cancer (NSCLC) showed “promising” overall response rates and 6-month progression-free survival, with an acceptable safety profile. The study...

breast cancer
cardio-oncology

Risk of Ischemic Cardiotoxicity With Aromatase Inhibitors in Postmenopausal Patients With Early Breast Cancer

As reported in The Lancet Oncology by Lund et al, a Danish prospective cohort study showed no increased risk of ischemic cardiotoxicity with use vs no use of aromatase inhibitor treatment in postmenopausal patients with early-stage breast cancer. Study Details The study included identification of...

issues in oncology
breast cancer
kidney cancer
colorectal cancer
pancreatic cancer
prostate cancer
solid tumors

Neoadjuvant Therapy Yields Notable Outcomes in Triple-Negative Breast Cancer

The studies summarized below were reported online over the past month in The ASCO Post, generating a high number of visitors.  For comprehensive news of these studies and more, visit ASCOPost.com. Triple-Negative Breast Cancer: Phase III KEYNOTE-522 The phase III KEYNOTE-522 trial has...

breast cancer

NCI Grant May Facilitate Development of Breast CT Screening Technology

The University of Arizona Health Sciences announced it has received a $3.3 million grant from the National Cancer Institute (NCI) of the National Institutes of Health to continue testing a novel imaging method for breast cancer detection that could provide an alternative to mammography. According...

breast cancer

Breast Cancer in 2024: Looking Back and Moving Forward

In a recent issue of The New York Times, Barron Lerner discussed Betty Ford’s breast cancer diagnosis in 1974.1 He described the state of the art of breast cancer treatment at the time and how her diagnosis accelerated the uptake of screening across the country. But her cancer was not...

leukemia
issues in oncology

Researchers May Have Uncovered Why Some AML Cells Resist Treatment

Researchers have provided new insights into acute myeloid leukemia (AML) and its resistance to venetoclax, according to a recent study published by Sango et al in Nature. Although AML is a rare disease, approximately 20,800 U.S. patients will be diagnosed in 2024, according to the American Cancer...

breast cancer
issues in oncology

How Hypoxia May Help Cancer Metastasize

Researchers have identified genes that breast cancer cells may use to survive in the bloodstream after escaping the low-oxygen regions of a tumor, according to a novel study published by Godet et al in Nature Communications. Each of the genes may serve as a potential therapeutic target to prevent...

lymphoma

A Diagnosis of Lymphoma Has Changed My Life

I’m 50, just a year older than my father was when he died of colorectal cancer. I was 14 when my dad died, so to me, cancer has always been synonymous with death. From a young age, my brothers and I had a goal: to make sure we packed in enough life before age 50. It never occurred to us that death ...

issues in oncology
global cancer care

From Gaps to Bridges: Cancer Care Rooted in Equity, Quality, and Value

“Inequities are a major obstacle in delivering safe, timely, respectful, and affordable cancer care globally,” commented moderator John Varallo, MD, MPH, FACOG, of the Global Surgery Foundation, at the Union for International Cancer Control (UICC) World Cancer Congress (WCC) 2024 in Geneva.1...

hepatobiliary cancer

Addition of Atezolizumab Plus Bevacizumab to Chemotherapy in Advanced Biliary Tract Cancer

In a phase II trial (IMbrave151) reported in the Journal of Clinical Oncology, Macarulla et al found that atezolizumab/bevacizumab plus chemotherapy produced a “modest” improvement in progression-free survival vs atezolizumab/placebo plus chemotherapy in first-line treatment of patients with...

issues in oncology
head and neck cancer

Study Finds Cisplatin Shortage Led to Treatment Alternatives for Head and Neck Cancer, Significantly Increasing Cost

The alternative use of the monoclonal antibody cetuximab during the shortage of cisplatin in the treatment of head and neck cancer resulted in a 16% total cost increase, leading to a 144-fold increase in costs at the administrative level, impacting payer costs and patient cost-sharing amounts....

breast cancer

Next-Generation Oral SERD in Postmenopausal Women With ER-Positive, HER2-Negative Advanced Breast Cancer

In a phase II trial (SERENA-2) reported in The Lancet Oncology, Oliveira et al found that the next-generation oral selective estrogen receptor degrader (SERD) camizestrant improved progression-free survival vs fulvestrant in postmenopausal women with estrogen receptor (ER)-positive, HER2-negative...

global cancer care

18 Researchers and Mentors Selected for ASCO’s Inaugural International Clinical Research Scholars Program in Latin America

ASCO has announced the participants and mentors selected for its new International Clinical Research Scholars (ICR) program. Eighteen scholars were selected by the ASCO Latin America Regional Council to take part in this 1-year program that pairs clinical research training with mentorship...

issues in oncology

Physician Wellness and Professional Burnout

According to an ASCO-sponsored study of burnout and career satisfaction among U.S. oncologists, 44.7% of surveyed oncologists reported feeling symptoms of burnout. ASCO offers information, practical advice, and member perspectives on how to prevent and manage burnout and prioritize wellness in your ...

lung cancer

Tarlatamab-dlle for Previously Treated Extensive-Stage SCLC

On May 16, 2024, tarlatamab-dlle (Imdelltra) was granted accelerated approval for extensive-stage small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.1 Tarlatamab is a bispecific delta-like ligand 3 (DLL3)-directed CD3 T-cell engager. Supporting Efficacy...

breast cancer

William Gradishar, MD, on Advances in Endocrine Therapeutic Options for Patients With ER-Positive, HER2-Negative Breast Cancer

William Gradishar, MD, discusses advances in endocrine therapeutic options for patients with estrogen receptor–positive, HER2-negative breast cancer, in follow-up to his presentation at the Lynn Sage Breast Cancer Symposium, October 2024. Dr. Gradishar is the Betsy Bramsen Professor of Breast...

solid tumors

Resection of Stage I to III Thymic Tumors in High-Volume U.S. Centers

In a study reported in a research letter in JAMA Surgery, Sakowitz et al found that R0 resection was more commonly achieved in patients with stage I to III thymic tumors who received surgery at high-volume centers (HVCs) for thymectomy in the United States. Study Details and Results The study...

breast cancer
survivorship

Risk of Second Primary Cancers After Breast Cancer in BRCA1 and BRCA2 Pathogenic Variant Carriers

In an English study reported in the Journal of Clinical Oncology, Allen et al found that patients with breast cancer harboring BRCA1/BRCA2 pathogenic variants were at high risk of second primary cancers. Study Details and Results The study involved follow-up of 25,811 females and 480 males...

lung cancer
issues in oncology

$2.5 Million Grant May Help Increase Lung Cancer Screenings in Underserved Communities

Researchers from the Health Jonsson Comprehensive Cancer Center, the David Geffen School of Medicine, and the Fielding School of Public Health at the University of California, Los Angeles (UCLA) were awarded a $2.5 million grant from the independent charitable organization Bristol Myers Squibb...

prostate cancer
issues in oncology

Case Study Shows Striking Improvements in Patient Treated for Metastatic Prostate Cancer With Antibody-Drug Conjugate

A landmark case report suggested a potential breakthrough in the treatment of an aggressive type of prostate cancer, according to a recent study published by Lap et al in the Annals of Internal Medicine. The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) was approved by the U.S....

gynecologic cancers
hepatobiliary cancer
lung cancer

Unexpected Results in Solid Tumors: What We Learned From Negative Findings

Attendees at the European Society for Medical Oncology (ESMO) Congress 2024 heard the results of many positive clinical trials that will advance the field of cancer treatment. However, a few late-stage trials of promising adjuvant therapies unexpectedly reported negative results. The ASCO Post...

gynecologic cancers

Trends in Use of Primary Cytoreductive Surgery and Neoadjuvant Chemotherapy in Advanced-Stage Ovarian Cancer

In a study reported in a research letter in JAMA Network Open, Bercow et al found reduced use of primary cytoreductive surgery (PCS) and increased use of neoadjuvant chemotherapy (NACT) followed by interval cytoreductive surgery (ICS) in patients with advanced epithelial ovarian cancer during...

bladder cancer

Durvalumab Plus Chemotherapy Improves Overall Survival in Localized Muscle-Invasive Bladder Cancer

The addition of the PD-L1 inhibitor durvalumab to standard neoadjuvant gemcitabine/cisplatin chemotherapy has demonstrated statistically significant and clinically meaningful improvements in survival compared with neoadjuvant chemotherapy in cisplatin-eligible patients with muscle-invasive bladder...

cardio-oncology
immunotherapy

When Cancer and Cardiovascular Disease Intersect

The annual Global Cardio-Oncology Summit (GCOS) was held September 22 to 24 in Minneapolis, with 430 health-care professionals attending from 20 countries. The Summit brings together health-care professionals from diverse disciplines including members of the International Cardio-Oncology...

issues in oncology
immunotherapy
genomics/genetics

Eyeing the Future of Oncology: Highlights From the Presidential Symposium at ESMO Congress 2024

At the European Society for Medical Oncology (ESMO) Congress 2024, the Eyes to the Future Presidential Symposium showcased innovative approaches in personalized medicine, immunotherapy resistance, and artificial intelligence (AI)-driven pathology analysis. These presentations, focusing on the...

multiple myeloma

Evolving Role of MRD Status in Multiple Myeloma

The use of measurable (or minimal) residual disease (MRD) status to guide treatment in multiple myeloma has become a topic of intense interest. Phase III studies presented at the Plenary Session of the 2024 International Myeloma Society Annual Meeting moved MRD status ever closer to validation in...

Jennifer Bickel, MD, Named MD Anderson Vice President and Chief Wellness Officer

The University of Texas MD Anderson Cancer Center recently announced the selection of Jennifer Bickel, MD, as the institution’s inaugural Vice President and Chief Wellness Officer (CWO). She will assume this role on January 6, 2025. Working closely with the Shibu Varghese, MA, Senior Vice...

skin cancer
immunotherapy
issues in oncology

Immunotherapy Combination May Demonstrate Benefit in Patients With Cutaneous Melanoma

Presurgical treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab may improve tumor control in patients with stage III cutaneous melanoma, according to a recent study published by Davar et al in Cancer Cell. The findings provided insights that could help advance...

solid tumors
hematologic malignancies
issues in oncology
genomics/genetics

Novel Method for Liquid Biopsies May Streamline Cancer Detection

Researchers have discovered a novel strategy to detect cancer cells with a liquid biopsy designed to be simpler, quicker, and more informational compared with current methods, according to a recent study published by Walker et al in Small. Background Current methods for detecting cancer cells may...

issues in oncology
supportive care

Prediction of Fracture Risk in Patients With Cancer

In a Canadian population–based cohort study reported in JAMA Oncology, Ye et al found that patients with cancer were at increased risk of fracture compared with individuals without cancer. In addition, a Fracture Risk Assessment Tool (FRAX) provided accurate prediction of this increased risk. As...

lymphoma

Valemetostat in Relapsed or Refractory Peripheral T-Cell Lymphoma

In a phase II trial (VALENTINE-PTCL01) reported in The Lancet Oncology, Zinzani et al found that valemetostat—a novel dual inhibitor of EZH1 and EZH2—was active in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Study Details In the trial, 133 patients with relapsed or...

breast cancer

Sunil S. Badve, MD, FRCPath, on Tumor-Infiltrating Lymphocytes in the Patient With Breast Cancer

Sunil S. Badve, MD, FRCPath, discusses research on tumor-infiltrating lymphocytes in the patient with breast cancer, based in part on his presentation at the Lynn Sage Breast Cancer Symposium, October 2024. Dr. Badve is Professor, Department of Pathology and Laboratory Medicine, and Vice Chair,...

Advertisement

Advertisement




Advertisement